Metastatic Colorectal Cancer
Conditions
Brief summary
The primary objective of this study is to determine whether systemic chemotherapy combined with hepatic arterial infusion with floxuridine and dexamethasone can increase the complete resection rate (R0) and improve the overall survival in patients with initially unresectable colorectal liver metastasis.
Detailed description
Recent studies and our experience have proved the efficacy and safety of systemic chemotherapy combined with hepatic arterial infusion (HAI) with floxuridine and dexamethasone in patients with initially unresectable colorectal liver metastasis. However, most of them are retrospective studies, phase I or II clinical researches, which could not provide high-level evidence. Therefore, we designed this study to determine whether systemic chemotherapy combined with HAI can increase the complete resection rate (R0) and improve the overall survival in patients with initially unresectable colorectal liver metastasis.
Interventions
DRUGmFOLFOX6
Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
DRUGHAI
Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump. This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
Sponsors
Yuhong Li
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-70 years old * Histologically confirmed colorectal adenocarcinoma * Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis * Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary team (MDT) * With no prior treatment for liver metastasis, including chemotherapy, operation, radiotherapy, transcatheter hepatic arterial chemoembolization (TACE) and targeted therapy * Without extra-hepatic metastasis confirmed by CT, MRI or PET/CT (if necessary) scanning * With adequate bone marrow function: platelets ≥ 90 x 109/L; white blood cells ≥ 3×109/L; absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Serum bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN * Patient has no ascites and with adequate blood coagulation function, albumin ≥ 35 g/L * Grade A level of Child-Push Liver Function * Creatinine ≤ 1× ULN, or Calculated Creatinine Clearance \>50ml/min （Cockcroft-Gault Equation） * ECOG performance status of 0-2 * Life expectancy ≥ 3 months * Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it) * Patients have provided a signed Informed Consent Form * With good compliance
Exclusion criteria
* With any extra-hepatic metastasis and/or primary tumor recurrence * Severe arterial embolism or ascites * With hemorrhagic tendency or coagulation disorders * Hypertensive crisis or hypertensive encephalopathy * Severe and uncontrolled systemic complications such as infections or diabetes * Serious cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension even with appropriate drug intervention, unstable angina pectoris, congestive heart failure (NYHA 2-4 degree), arrhythmia that needs medication intervention * Patient who has suffered from central nervous system diseases such as primary brain tumor, uncontrolled epilepsy even with standard treatment, any brain metastasis or stroke * Patient who has a concurrent malignancy or has a malignancy within 5 years before study enrollment, (with the exception of radically resected skin basal cell carcinoma or cervical carcinoma in situ) * Patient who has received any investigational antineoplastic agent within 28 days before the enrollment * Any residual toxicity from prior chemotherapy (with the exception of alopecia), such as grade 2 or more sensory peripheral neuropathy (NCI CTC v3.0), oxaliplatin-based regimen will not be considered * Patient who is allergic to oxaliplatin, leucovorin, 5-Fluorouracil, floxuridine or dexamethasone * Pregnant or lactating women * Patient who does not use or refuses to take any appropriate contraceptive measures (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel or sterilization operation), including women of childbearing age (within 2 years after the last menstrual period) and men who are with possible fertility * Unable or unwilling to comply with the research plan * The existence of any other disease, dysfunction caused by metastatic lesions, or suspicious disease found on the regular examination, which indicating contraindications to the use of study drugs or may bring high risks of treatment related complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms | Up to 2-4 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| R1 resection rates (with microscopic residual tumor) of both arms | Up to 2-4 monthes | — |
| Specific R0/R1 resection plus radiofrequency ablation rates of both arms | Up to 2-4 monthes | — |
| Recurrence-free survival (RFS) of both arms | Up to 5 years | Time to recurrence or death |
| Overall response rates (ORR) of both arms | Up to 4-8 monthes | — |
| Progression free survival(PFS) of both arms | From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 monthes | — |
| Overall survival (OS) of both arms | From the date of first drug administration until the date of death, assessed up to 5 years | — |
| Number of participants with surgical complications, AES and SAEs as a measure of safety | Each follow up visit, assessed up to 2 years | — |
| 5 year cancer specific survival rate of the whole population | Up to 5 years | — |
Countries
China
Contacts
Primary ContactYu-hong Li, MD, Ph D
Outcome results
None listed